Company: MIRA
Filing Date: 2025-07-29
Form Type: PRER14A
Source: 0001641172-25-021434
Chunk: 225

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-07-29
Form: PRER14A
Chunk 225
---
Moore Financial Consulting

| Moore                
 Financial Consulting |

Annex E

<div align='center'>EXCLUSIVE LICENSE
AGREEMENT</div>

THIS EXCLUSIVE LICENSE AGREEMENT
(this “Agreement”) is entered into as of March 16, 2025, (the “Effective Date”), and as amended as of May 28,
2025, by and between MIRALOGX LLC, a Florida limited liability company located at 3014 West Palmira Ave., Suite 200, Tampa, FL 33629 (“Licensor”),
and SKNY PHARMACEUTICALS, INC., a Delaware corporation having its principal place of business at 3014 West Palmira Ave., Suite 302, Tampa,
FL 33629 (“Licensee”). Licensor and Licensee are each herein referred to as “Party” and collectively as the “Parties.”

WHEREAS, Licensor is the
owner of certain intellectual property pertaining to antiinflammatory compounds and associated pharmaceutical formulations and therapeutic
treatment methods; and

WHEREAS, Licensee desires
to commercially develop a drug product containing as an active agent 3a-isopropyl-2-methyl-6-propyl-3a,8b-dihydro-1H-cyclopenta[b] benzofuran-8-ol
(sometimes referred to by the Parties as “T-55”) or a pharmaceutically acceptable salt, ester or ether thereof, and/or 8-hydroxy-3a-isopropyl-2-methyl-6-propyl3a,8b-dihydro-1H-cyclopenta[b]benzofuran-7-carboxylic
acid (sometimes referred to by the Parties as “M308”) or a pharmaceutically acceptable salt, ester or ether thereof.

NOW, THEREFORE, for good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

<div align='center'>ARTICLE 1—DEFINITIONS</div>

1.1 “Licensed Product”
shall mean a drug product containing as an active agent 3aisopropyl-2-methyl-6-propyl-3a,8b-dihydro-1H-cyclopenta[b]benzofuran-8-ol or
a pharmaceutically acceptable salt, ester or ether thereof (“T-55”), and/or 8-hydroxy-3aisopropyl-2-m